SYRE
NASDAQSpyre Therapeutics Inc.
Price$75.05-3.17 (-4.05%)
01:30 PM07:45 PM
News · 26 weeks70+67%
2025-12-142026-06-07
Mix4290d
- Insider16(38%)
- SEC Filings10(24%)
- Other9(21%)
- Offering4(10%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018
- INSIDERChief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Financial Officer Burrows Scott L sold $532,937 worth of shares (7,500 units at $71.06) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $14.50 (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAEnrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA Across SKYWAY and SKYLINE trials, planned ‘6 in '26' Phase 2 readouts enabled and on track Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR) WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more compl
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERSEC Form 4 filed by Director Albers Jeffrey W.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERSEC Form 4 filed by Director Henderson Michael Thomas4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERSEC Form 4 filed by Director Mckenna Mark C.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERSEC Form 4 filed by Director Milligan Sandra4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially
- PRSpyre Therapeutics to Participate in Upcoming June Investor ConferencesWALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference – New YorkDate: Wednesday, June 3, 2026Fireside Time: 12:15 pm ET Event: Goldman Sachs 47th Annual Global Healthcare Conference – MiamiDate: Monday, June 8, 2026Fireside Time: 10:00 am ET Members of the Spyre management team will also host one-on-one investor meetings
- INSIDERDirector Henderson Michael Thomas sold $5,952,050 worth of shares (80,000 units at $74.40) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 88,606 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- SECSEC Form 10-Q filed by Spyre Therapeutics Inc.10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateAnnounced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis ("RA") sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering ofcommon stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026, with ex
- INSIDERChief Financial Officer Burrows Scott L exercised 12,500 shares at a strike of $14.50 and sold $892,125 worth of shares (12,500 units at $71.37) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Medical Officer Sloan Sheldon exercised 78,333 shares at a strike of $27.46 and sold $5,600,701 worth of shares (78,333 units at $71.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,070,507 worth of shares (15,000 units at $71.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 612,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on May 1, 2026 a
- SECSEC Form SCHEDULE 13G filed by Spyre Therapeutics Inc.SCHEDULE 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)
- SECSEC Form 8-K filed by Spyre Therapeutics Inc.8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
SYRE FAQ
6 questionsWhere does SYRE stock trade?
Spyre Therapeutics Inc. (SYRE) is listed on NASDAQ.What sector and industry is SYRE in?
Spyre Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spyre Therapeutics Inc. go public?
Spyre Therapeutics Inc. (SYRE) completed its IPO in 2016.What are analysts saying about SYRE?
Spyre Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy on 2026-04-14. Recent price targets range from $2700.00 to $4500.00.What companies are similar to SYRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SYRE side-by-side with any of them on Quantisnow.How can I track SYRE on Quantisnow?
Quantisnow aggregates Spyre Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYRE to receive live email and push alerts on every new disclosure.